NewAmsterdam Pharma Company's total assets for Q3 2025 were $786.43M, a decrease of -3.52% from the previous quarter. NAMS total liabilities were $58.36M for the fiscal quarter, a 59.38% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.